FORMULATION AND EVALUATION OF DOCETAXEL TRIHYDRATE LOADED SELF-ASSEMBLED NANOCARRIERS FOR TREATMENT OF HER2 POSITIVE BREAST CANCER
Journal Title: Journal of Drug Delivery and Therapeutics - Year 2017, Vol 7, Issue 6
Abstract
Human Epidermal Growth Factor Receptor 2-positive (HER2-positive) breast cancer tend to be more aggressive among all breast cancers. Breast cancers with HER2 gene amplification or HER2 protein overexpression are called HER2-positive. It tends to grow faster and are more likely to spread and come back compared to HER2-negative breast cancers. HER2 positive breast cancer is often treated with chemotherapy drugs called anthracylines (e.g. doxorubicine, epirubicine), taxanes (e.g. Docetaxel, peclitaxel) as well as some others, usually in combination of two or more chemotherapy drugs1 but the development of potential drug delivery system by using nanotechnology is also the important aspect for the proper treatment of HER2 positive breast cancer. The aim of this study was to develop DTX-loaded self assembled nanocarriers (SANs) for treatment of HER2 positive breast cancer and also to evaluate their efficacy to release the drug by controlled manner. SANs were prepared from a glyceryl monooleate, Pluronic® F127 (0.5 – 1.5 % w/v) and Pluronic® F68 (0.25-1.0 %w/v) in different concentration with or without docetaxel trihydrate (DTX) (2.0%w/v) by high pressure homogenization, before preparation compatibility of drug and polymers was studied by differential scanning calorimetry (DSC) and FTIR spectroscopy. Prepared SANs was then subject to different evaluation test particle size, zeta potential, % entrapment efficiency, drug content, in vitro drug release study, measurement of pH, and stability study. Particle size of SANs prepared with Pluronic® F127 was found in the range of 170 nm to 280 nm whereas SANs with Pluronic® F68 was found between 200 to 240 nm and it shows more negative zeta potential value than -30 mV. More than 90 % of DTX was found to be entrapped in SANs formulations loaded with DTX 2.0% w/v. Drug released study revealed that formulation F9 containing 0.25% PF68 shows 89.59 % release after 12 h and F5 containing 1.0% PF127 releases 96.56% drug after 12 h. Results of one month stability study shows that the SANs formulations were found to be stable over a one month. Hence, the DTX-loaded SANs was act as an potential drug carrier to fulfill the demand of cancer therapeutics.
Authors and Affiliations
Nilesh Ramesh Rarokar
TRANSDERMAL PATCH OF RAMIPRIL LOADED CHITOSAN NANOPARTICLES DISPERSED IN CARBOPOL GEL
The main aim to improve the systemic bioavailability of Ramipril by the design of transdermal drug delivery based on chitosan nanoparticles dispersed into gels. When chitosan nanoparticles dispersed into gels consisting...
NATURAL PRODUCTS USED AS ANTI-CANCER AGENTS
In the present time Natural products are considered to be symbols of protection in comparison to the synthetic product that are regarded as unsafe to human life and environment. Although a large number of synthetic drugs...
ENVIRONMENTAL RESPONSIVE HYDROGELS: A NOVEL APPROACH IN DRUG DELIVERY SYSTEM
Hydrogels are three dimensional crosslinked hydrophilic polymeric networks which has the capability to imbibe water or biological fluids. Environmentally responsive hydrogels have the ability to respond to change in thei...
WOUND REPAIR AND REGENERATING EFFECT OF EUGENOL ISOLATED FROM ETHYL ACETATE SOLUBLE FRACTION OF ETHANOLIC EXTRACT OF CINNAMOMUM TAMALA LEAVES IN STZ DIABETIC RATS
Diabetes is a chronic hyperglycaemic disorder; leads to developed several complications including delayed wound healing after any injury. These non-healing wound ends up to organ or limb salvage. The available modern med...
EMPATHY AND SYMPATHY AMONG MEDICAL STUDENTS: CHANGING TRENDS
Objectives: There is general belief that empathy is crucial for the physician-patient relationship and thus an important issue in medical education. This comparative study was designed to establish the changing attitude...